BioPharma Today

China's New 2020 Approach: Rewriting the Rules of Competition in 2012 and Beyond

China has radically altered the structure, economics, and competitive landscape of a host of industries: textiles and garments in the 1980s, consumer electronics and industrial chemicals in the 1990s, and automotives and telecommunications equipment in the 2000s. In most cases, the resulting transformation has been highly disruptive, creating an unexpected new caste of clear winners and losers, who all held a common belief to their detriment: our industry won’t change.

Coming In Thursday's "The Pink Sheet" DAILY - Lipitor Goes Generic

Watson ships more than 1 million atorvastatin tablets on the first day of generic Lipitor availability.

Latest News From "The Pink Sheet" DAILY - FDA Clears Ranbaxy's Punjab Manufacturing Site

Shot In The Arm: U.S. FDA Approves Ranbaxy's Finished Dose Unit At Mohali; Company May Shore Up Product Filings U.S. FDA clears Ranbaxy's Punjab manufacturing site, clearing the Indian company to start shipping products to the U.S. again as Lipitor mystery continues.

Editor's Picks From The World Press

Business & Finance

AstraZeneca commits $100 million to MedImmune Ventures
PharmaTimes (U.K.) Nov. 29, 2011

PTC and Roche sign $490M deal for muscular atrophy drugs
MedCityNews.com Nov. 29, 2011

Infinity receives $50 million from R&D partner Mundipharma
Mass High Tech (Boston) Nov. 29, 2011

Government & Legal News

Industry urges passage of bill to encourage Medicaid's generics use
National Journal Nov. 28, 2011

Canada also revokes Avastin's approval for breast cancer
The Globe and Mail (Toronto) Nov. 28, 2011

FDA accelerates review of Pfizer and Bristol's anti-coagulant Eliquis
The Wall Street Journal Nov. 30, 2011, Reuters Nov. 29, 2011

EU authorizes Komboglyze and widens approval of Onglyza
PharmaTimes (U.K.) Nov. 29, 2011

FDA OKs Watson's generic of birth control pill Yaz
The Wall Street Journal Nov. 29, 2011

Gilead obtains EU approval of combo HIV pill Eviplera
PharmaTimes (U.K.) Nov. 29, 2011

Onyx's blood cancer drug carfilzomib is accepted for FDA review
American City Business Journals Nov. 29, 2011

Pipeline/R&D News

Study will combine breast cancer drugs from Genentech and Galena
American City Business Journals Nov. 28, 2011

Search for AIDS cure is making a comeback
The New York Times (tiered subscription model) Nov. 28, 2011

Coming In Wednesday's "The Pink Sheet" DAILY - Supreme Court To Decide If Sales Reps Qualify For Overtime Pay

Pharmaceutical companies and sales representatives will finally get a national rule on whether reps qualify for overtime pay as the Supreme Court has agreed to hear a case involving GlaxoSmithKline reps. The court will address whether the Fair Labor Standards Act’s overtime pay exemption for outside sales employees applies to pharmaceutical sales representatives and whether the Secretary of the Department of Labor should be given deference in interpreting the law.

Latest News From "The Pink Sheet" DAILY - Elan, University of Cambridge Launch Center To Focus On Alzheimer's

Civitas' Inhaled L-Dopa Candidate To Start Phase 1, Backed by Michael J. Fox Foundation Grant Parkinson's disease is crowded, but Civitas' value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.

Editors' Picks From The World Press

Business & Finance

Onyx reportedly considers a company sale
Bloomberg Nov. 28, 2011

Record-Setting Deal For Pharmasset Expected To Boost Value Of Other HCV Biotechs

Article preview from "The Pink Sheet"-  November 21, 2011

The $11 billion Gilead plans to pay for Pharmasset dwarfs any prior deal for a clinical-stage biotech, and should be good news for other biotechs with hepatitis C candidates, like Inhibitex, Achillion and Idenix.

Coming In Tuesday's "The Pink Sheet" DAILY - Industry Faults FDA Draft Guidance On Clinical Trial Imaging Endpoints

AstraZeneca has committed another $100 million to MedImmune Ventures, the venture investment arm of its MedImmune subsidiary. The evergreen fund, which invests in both early- and late-stage startups worldwide, now has $400 million under management. Concurrently, the fund announced that it has backed Australian startup NeuProtect, which addresses cardiac remodeling following myocardial infarction.

Latest News From "The Pink Sheet" DAILY - NICE Rejects Lucentis Use In Secondary Eye Indications

U.K. Cost Watchdog Rejects Lucentis' Extended Use In Eye Disease NICE's draft rejection of Lucentis for use in secondary ophthalmologic indications comes as competition looms from Eylea in key AMD setting.